Cellular Immunotherapy Study for Brain Cancer

Phase 1

Completed

• Conditions: Anaplastic Astrocytoma; Gliomas; Anaplastic Oligodendroglioma; Malignant Meningioma; Anaplastic Mixed Glioma; Glioblastoma Multiforme
• Interventions: Drug: alloreactive CTL

• Registration Number: NCT01144247
• Lead Sponsor: Jonsson Comprehensive Cancer Center

Brief Summary

The purpose of this research study to determine if treating recurrent malignant gliomas with another person's (donor) immune system cells known as aCTL cells, will be safe. This study will also try to determine if persons who receive aCTL's are more or less likely to survive their brain tumor than persons who had similar tumors in the past. Approximately 15 patients will be enrolled at UCLA.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2010-06-11
• Study First Submitted QC: 2010-06-14
• Study First Posted: 2010-06-15
• Study Start: 2010-07
• Primary Completion: 2015-07
• Study Completion: 2015-07
• Status Verified: 2016-05
• Last Update Submitted: 2016-05-26
• Last Update Posted: 2016-05-27

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 10

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
alloreactive CTL arm	alloreactive CTL	-

Primary Outcome Measures

Name	Time	Method
Number of patients with adverse events as a measure of safety and tolerability	5 years

Secondary Outcome Measures

Name	Time	Method
Maximum tolerated dose	3 years

Trial Locations

Locations (1)

University of California, Los Angeles; 🇺🇸 Los Angeles, California, United States